# A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

> **NCT00920257** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 77 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** GSK2141795

## Key facts

- **NCT ID:** NCT00920257
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-16
- **Primary completion:** 2013-04-17
- **Final completion:** 2013-04-17
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920257, "A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00920257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*